Scleroderma Patients At Greater Risk Of Myocardial Infarction Within First Year PDF Print E-mail
Sunday, 22 December 2013 21:29
According to the first large population-based cohort study of its kind, patients with Systemic Sclerosis or Scleroderma were found to be at a greater than eightfold increased risk of having an acute myocardial infarction (MI) during their first year after diagnosis. After that first year however, the risk drops off over time.

Still, during the five years post diagnosis the MI risk remains more than three times that of the matched general population, Dr. J. Antonio Avina-Zubieta reported at the annual meeting of the American College of Rheumatology. "Our findings support increased vigilance in cardiovascular disease prevention, surveillance, and risk modification in patients with systemic sclerosis," declared Dr. Avina-Zubieta, a rheumatologist at the University of British Columbia, Vancouver.

Dr. Avina-Zubieta and his fellow investigators harnessed comprehensive provincial medical databases to identify all 1,245 adults diagnosed with rheumatologist-confirmed systemic sclerosis (SSc) in British Columbia during 1996-2010. The SSc patients averaged 53 years of age at the time of their rheumatologic diagnosis. Eighty-three percent were women.

During a mean follow-up period of 3.5 years following diagnosis of SSc, 89 patients experienced an acute MI, as did 289 controls. This translated to an incidence rate of 20.2 cases per 1,000 person-years among patients with SSc, compared with 5.3 per 1,000 among controls.

The risk was 8.2-fold greater in SSc patients than controls during the first year after diagnosis and 3.5 times greater during years one to five years after diagnosis, but once patients got more than 5 years out from diagnosis there was no longer any significant increase in MI risk.

Patients with SSc who were in the 45- to 59-year-old age group were at greatest risk: They were 7.4 times more likely than controls to have an MI. SSc patients aged 60-74 years had a 4.4-fold greater risk of MI than did controls, and those aged 75 years and older were at 5.6-fold increased risk.

It is well established that patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have an increased risk of premature atherosclerotic disease. Up until now, however, information about the risk of major adverse cardiovascular events in patients with SSc has been scarce and has come from nondefinitive studies in selected populations or cross-sectional studies lacking adequate adjustment for potential confounding factors, according to Dr. Avina-Zubieta.

Why the sharp increase in MI risk during the first year after diagnosis of SSc? He offered two hypotheses. One is that this is a time of particularly great inflammatory load as physicians work to get the disease under control. Also, there is a phenomenon Dr. Avina-Zubieta called "the depletion of susceptibles," whereby, once the patients at higher risk have had their MI early on, those who remain aren’t at sufficient risk to stand out from the general population.

Source: Family Practice News
 
More articles :

» Medical Research Trends to Watch in 2012

1. NCATS: Who moved my cheese?This year, the National Institutes of Health will establish its new (NCATS), created to speed the translation of basic discoveries into therapies that will improve public health. Solutions can be tough to develop, and...

» UT Researchers At Forefront Of Efforts To Stem The Tide Of Autoimmune Diseases

Autoimmune and autoinflammatory diseases are on the rise and researchers and physicians at are at the forefront of efforts to stem the tide. These diseases are often hard to diagnose and often affect individuals differently.Autoimmune and...

» Causes Found for Stiff Skin Conditions

By studying the genetics of a rare inherited disorder called stiff skin syndrome, researchers at the Johns Hopkins University School of Medicine have learned more about , a condition affecting about one in 5,000 people that leads to hardening of the...

» No Exercise Benefit with Bosentan in Systemic Sclerosis

Treatment with the endothelin receptor antagonist bosentan () failed to improve exercise capacity in patients with systemic sclerosis, a randomized trial found. After one year of treatment, there was a nonsignificant mean change in the six-minute...

» Nutrition & Dietary Supplements

A comprehensive treatment plan for may include a range of complementary and alternative therapies. Individuals with Scleroderma tend to have deficiencies in many vitamins and minerals. Ask your team of health care providers about the best ways to...

» arGentis Expands Scientific Advisory Board

is a diversified biopharmaceutical development company located in Memphis, Tennessee. The company’s pipeline consists of mid- and late-stage platform technologies in both autoimmunity and ophthalmology. According to , the company announced...